Coming down heavily on critics expressing doubts about the Bharat Biotech’s indigenously developed coronavirus vaccine Covaxin, the Hyderabad-based biotech major’s managing director Dr Krishna Ella on Monday slammed the critics …
Biotech
-
- News
News18 Daybreak | ‘Carried Out 200% Honest Trials’: Bharat Biotech Top Boss on Critics ‘Bashing’ Covaxin, Govt to Hold Talks With Farmers Again and Other Stories You Need to Watch Out For
Jan 05, 2021 08:21 AM IST Daybreak ‘Won’t Hurt Anyone, Carried Out 200% Honest Trials’: Bharat Biotech Top Boss on Critics ‘Bashing’ Covaxin Amid questions raised by industry experts and …
- News
Shashi Tharoor critcises Centre for giving nod to Bharat Biotech vaccine without phase 3 trials
Congress leader Shashi Tharoor has criticised the government for giving the nod to Bharat Biotech’s COVID-19 vaccine without phase-3 trials. The central licensing authority has granted permission to Bharat Biotech …
-
The head of Bharat Biotech expressed confidence at a press conference on Monday that Covaxin, the vaccine candidate developed by the company, will be effective on mutant strains of the …
- News
Covaxin trials conducted with ‘200% honesty’, says Bharat Biotech MD; new COVID-19 cases under 20,000 for 3rd day – Health News , Firstpost
The global efforts to curb the spread of COVID-19 got a boost in the UK, as it became the first country to administer a vaccine against the virus Hitting out …
-
Amid questions raised by experts and Opposition over the restricted use approval given to Covaxin despite no efficacy data from Phase III trials, Bharat Biotech MD Krishna Ella Monday said …
- News
Coronavirus News Live Updates: Bharat Biotech presser soon amid concerns over ‘hasty’ Covaxin approval – India News , Firstpost
Coronavirus News Live Updates: Some Congress leaders had on Sunday raised serious concern over the grant of approval to Bharat Biotech’s COVID-19 vaccine for restricted use, saying it is ‘premature’ …
-
The Central Licensing Authority on Sunday granted permission to Hyderabad-based Bharat Biotech to manufacture ‘Covaxin’ for sale and distribution, after the indigenous coronavirus vaccine received regulatory approval for emergency use. …
- News
Bharat Biotech says DCGI approval for COVAXIN is ‘giant leap’ for India’s scientific capability – India News , Firstpost
The company’s managing director, Krishna Ella, claimed that COVAXIN has generated ‘excellent’ data regarding its safety, and robust immune responses to multiple viral proteins COVAXIN vaccine by Bharath Biotech. New …
-
Hyderabad: Bharat Biotech has successfully recruited 23,000 volunteers, and continued progress towards achieving the goal of 26,000 participants for Phase-3 clinical trial of its COVID-19 vaccine Covaxin across multiple sites …
- News
Coronavirus News LIVE Updates: Bharat Biotech recruits 26,000 volunteers for Phase 3 COVAXIN trials which began November 2020 – India News , Firstpost
Coronavirus News LIVE Updates: The company’s chairman Dr Krishna Ella called DGCI’s approval for COVAXIN ‘a giant leap for innovation and novel product development in India’ Coronavirus News LATEST Updates: Expressing …
- News
Pfizer-BioNTech requests more time, India’s SEC to meet on January 1 to authorise SII, Bharat Biotech vaccines
India’s Subject Expert Committee (SEC) in Central Drugs Standard Control Organisation (CDSCO) met on Wednesday to consider coronavirus vaccines for emergency use authorisation (EUA) requested by Pfizer-BioNTech, Bharat Biotech and …
-
Bharat Biotech Chairman and Managing Director Dr Krishna Ella and Joint Managing Director Suchitra Ella called on Vice-President M Venkaiah Naidu at his residence on Friday in Hyderabad. They discussed …
-
Hyderabad: Prominent drug firm Bharat Biotech has submitted the phase-2 study results of Covaxin in 380 participants and stated that the vaccine against Covid-19 has accelerated the response from immune …
- General
Superspreading Boston biotech conference in February is linked to 1.9 percent of all U.S. cases.
As many as 300,000 coronavirus cases across the United States can be traced to a two-day conference in Boston attended by 175 biotech executives in February, according to a study …
- News
DCGI expert panel asks SII, BHARAT Biotech to provide more safety, efficacy data for Covid-19 vaccines
In a major development related to COVID-19 vaccine, Subject Expert Committee (SEC) of Drugs Controller General of India (DCGI) has asked for more safety and efficacy data from Serum Institute …
- News
64 foreign envoys arrive at Bharat Biotech facility in Hyderabad that is developing Covid-19 vaccine
As the United Kingdom began administering people with the Pfizer-BioNTech vaccine, foreign delegates from more than 60 countries on Wednesday arrived in Hyderabad to visit leading biotech companies in India …
- News
Bharat Biotech seeks emergency use authorisation for Indian Covid-19 vaccine; expert panel to review
The Hyderabad-based pharmaceutical firm Bharat Biotech applied to the Drugs Controller General of India (DCGI) on Monday for granting emergency use authorisation for its COVID-19 vaccine Covaxin, becoming the third …
- News
Bharat Biotech seeks emergency use authorisation for Covaxin days after Pfizer and SII – India News , Firstpost
Last week, Prime Minister Narendra Modi had said that a COVID-19 vaccine ‘may be ready in a few weeks’ at an all-party meeting COVAXIN vaccine by Bharath Biotech. New Delhi: After …
-
Hyderabad: Prime Minister Narendra Modi visited Coronavirus vaccine facilities at Ahme-dabad, Hyderabad and Pune to review the development and manufacturing process on Monday. The visit was purely functional, and shorn …
-
Prime Minister Narendra Modi said Bharat Biotech, a city-based pharmaceutical company, is closely working with the Indian Council of Medical Research (ICMR) to create an indigenous Covid vaccine on Saturday. …
-
Prime Minister Narendra Modi on Saturday, visited Bharat Biotech, a Hyderabad-based Pharmaceutical company to know about the progress made in the development of indigenous coronavirus vaccine. The visit was part …
-
India’s pharmaceutical company Bharat Biotech International Ltd has now, months later, revealed that during Phase 1 of the human trial of COVID-19 vaccine, the company had an adverse event. In August …
- 1
- 2